
Zultan3 ml
Aristopharma Ltd.
Latanoprostene Bunod ophthalmic solution is FDA-approved for the following indication: Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Latanoprostene Bunod ophthalmic solution is FDA-approved for the following indication:
Latanoprostene Bunod is typically used as a first-line topical agent, either alone or, when IOP control is insufficient, as part of combination therapy with other IOP-lowering eye drops (e.g., beta-blockers, carbonic anhydrase inhibitors, or alpha-agonists) under a physician's guidance. There are no well-established guideline-supported uses beyond glaucoma/ocular hypertension, and no commonly recognized off-label indications for Latanoprostene Bunod.
| Indication | Dose | Notes |
|---|---|---|
| Open-angle glaucoma or ocular hypertension (adults) | One drop in the affected eye(s) once daily, in the evening | Do not exceed once daily — more frequent dosing may reduce the IOP-lowering effect |
If a dose is missed, treatment should continue with the next scheduled dose the following evening; do not double the dose. Latanoprostene Bunod should not be administered more than once per day.
The most common side effect of Latanoprostene Bunod is:
Other reported side effects include:
Less common but clinically important effects include gradual, permanent increase in brown iris pigmentation and macular edema (see Precautions and Warnings for details). Patients should report persistent, severe, or worsening eye symptoms to their physician.
Latanoprostene Bunod is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.